Annexin A5 levels in midtrimester amniotic fluid

Association with intrauterine growth restriction

Peter Van Eerden, Xiao Xuan Wu, Cynthia Chazotte, Jacob H. Rand

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The purpose of this study was to determine whether amniotic fluid levels of annexin A5 (AF-AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design: Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks' gestation and annexin A5 (AnxA5) levels were determined with enzyme-linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results: AF-AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF-AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF-AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR (P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF-AnxA5 may be a useful marker for identifying pregnancy abnormalities.

Original languageEnglish (US)
Pages (from-to)1371-1376
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume194
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Annexins
Second Pregnancy Trimester
Amniotic Fluid
Annexin A5
Growth
Pregnancy
Amniocentesis
Growth and Development
Enzyme-Linked Immunosorbent Assay

Keywords

  • Amniotic fluid
  • Amniotic fluid (AF)
  • Annexin A5 (AnxA5)
  • Antiphospholipid syndrome (APS)
  • Intrauterine growth restriction (IUGR)
  • Placenta
  • Placental vascular complications
  • Pregnancy complications

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Annexin A5 levels in midtrimester amniotic fluid : Association with intrauterine growth restriction. / Van Eerden, Peter; Wu, Xiao Xuan; Chazotte, Cynthia; Rand, Jacob H.

In: American Journal of Obstetrics and Gynecology, Vol. 194, No. 5, 05.2006, p. 1371-1376.

Research output: Contribution to journalArticle

Van Eerden, Peter ; Wu, Xiao Xuan ; Chazotte, Cynthia ; Rand, Jacob H. / Annexin A5 levels in midtrimester amniotic fluid : Association with intrauterine growth restriction. In: American Journal of Obstetrics and Gynecology. 2006 ; Vol. 194, No. 5. pp. 1371-1376.
@article{43f6813c8f92435a81faf9fdae3d3ef8,
title = "Annexin A5 levels in midtrimester amniotic fluid: Association with intrauterine growth restriction",
abstract = "Objective: The purpose of this study was to determine whether amniotic fluid levels of annexin A5 (AF-AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design: Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks' gestation and annexin A5 (AnxA5) levels were determined with enzyme-linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results: AF-AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF-AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF-AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR (P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF-AnxA5 may be a useful marker for identifying pregnancy abnormalities.",
keywords = "Amniotic fluid, Amniotic fluid (AF), Annexin A5 (AnxA5), Antiphospholipid syndrome (APS), Intrauterine growth restriction (IUGR), Placenta, Placental vascular complications, Pregnancy complications",
author = "{Van Eerden}, Peter and Wu, {Xiao Xuan} and Cynthia Chazotte and Rand, {Jacob H.}",
year = "2006",
month = "5",
doi = "10.1016/j.ajog.2005.11.005",
language = "English (US)",
volume = "194",
pages = "1371--1376",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Annexin A5 levels in midtrimester amniotic fluid

T2 - Association with intrauterine growth restriction

AU - Van Eerden, Peter

AU - Wu, Xiao Xuan

AU - Chazotte, Cynthia

AU - Rand, Jacob H.

PY - 2006/5

Y1 - 2006/5

N2 - Objective: The purpose of this study was to determine whether amniotic fluid levels of annexin A5 (AF-AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design: Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks' gestation and annexin A5 (AnxA5) levels were determined with enzyme-linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results: AF-AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF-AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF-AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR (P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF-AnxA5 may be a useful marker for identifying pregnancy abnormalities.

AB - Objective: The purpose of this study was to determine whether amniotic fluid levels of annexin A5 (AF-AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design: Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks' gestation and annexin A5 (AnxA5) levels were determined with enzyme-linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results: AF-AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF-AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF-AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR (P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF-AnxA5 may be a useful marker for identifying pregnancy abnormalities.

KW - Amniotic fluid

KW - Amniotic fluid (AF)

KW - Annexin A5 (AnxA5)

KW - Antiphospholipid syndrome (APS)

KW - Intrauterine growth restriction (IUGR)

KW - Placenta

KW - Placental vascular complications

KW - Pregnancy complications

UR - http://www.scopus.com/inward/record.url?scp=33646088960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646088960&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2005.11.005

DO - 10.1016/j.ajog.2005.11.005

M3 - Article

VL - 194

SP - 1371

EP - 1376

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 5

ER -